TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital
Initial $10 million draw extends cash runway to mid-2023SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:...
Pharmaceutical
Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...
Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting
LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing...
Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
Biotimize Announces the Opening of a Fundraising Round to Build the First Biological CDMO in Brazil
PIRACICABA, Brazil, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Biotimize, a functional growth-stage biotechnology as a service (BaaS) company with a...
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
SAN CARLOS, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative...
Alvotech Reports Update on Initial AVT02 Biologics License Application
REYKJAVIK, Iceland, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Alvotech Reports Update on Initial AVT02 Biologics License Application
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced...
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children...
Orion recalls Devisol Salmiakki dietary supplement from consumers
Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_230tabl Devisol_Salmiakki_20mikrog_230tablORION CORPORATION PRESS RELEASE 5 SEPTEMBER 2022 AT 8.00 EEST Orion recalls Devisol Salmiakki dietary supplement from consumers...
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) --...
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not...
Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding
Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical...
DBV Technologies to Present at Upcoming Investor Conferences
Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345...
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA...
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance...
Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors
Neha Krishnamohan Neha KrishnamohanWESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company...
Fate Therapeutics to Participate at Upcoming September Investor Conferences
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD,...